Sotorasib
Lumakras · KRAS G12C inhibitor
Newer agent; renal data emerging.
Mektovi · Bini
MEK inhibitor · approved 2018 · 9 citations · FAERS AKI reporting ROR 2.23 (95% CI 1.93–2.58, 185 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A MEK inhibitor whose renal signal is a modest creatinine rise — with rare rhabdomyolysis reports.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Clinically significant intrinsic nephrotoxicity is uncommon; modest creatinine elevations occur and CK elevation is a recognized MEK-class effect. In COLUMBUS, grade 3-4 blood-CK increase occurred in ~7% with encorafenib plus binimetinib; rare rhabdomyolysis can secondarily threaten the kidney.Source: Dummer et al., Lancet Oncol 2018 (COLUMBUS)
Weeks into therapy.
Distilled from: “Weeks into therapy.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Selective, reversible MEK1/2 inhibitor blocking MAPK signaling; given with encorafenib in BRAF V600-mutant melanoma.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the MEK inhibitor class.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Ophthalmic
Keratopathy, uveitis, retinopathy
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Kidney rows of the label's dosage tables
From the MEKTOVI label (Mar 2025) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. A cell marked fn carries one of those footnotes on the label. Educational only, not medical advice.
| Severity of Adverse Reactionfn | Dose Modification for MEKTOVI |
|---|---|
| • Grade 4 asymptomatic CPK elevation or • Any Grade CPK elevation with symptoms or with renal impairment | Withhold MEKTOVI dose for up to 4 weeks. • If improved to Grade 0-1 resume at a reduced dose. • If not resolved within 4 weeks, permanently discontinue MEKTOVI. |
Everything below is FAERS — adverse events someone chose to report, about 7,953 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,246 of 7,953 reports
Reported with hospitalization
2,314 of 7,953 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Binimetinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Lumakras · KRAS G12C inhibitor
Newer agent; renal data emerging.
Oncaspar · Enzyme (asparaginase)
Rare AKI; pancreatitis- and thrombosis-mediated.
Vesanoid · Retinoid (differentiating agent)
Differentiation syndrome → capillary leak and AKI.
Elzonris · IL-3 immunotoxin
Capillary-leak syndrome → AKI.
Talvey · Bispecific (GPRC5D×CD3)
CRS-related AKI — emerging.
Tecvayli · Bispecific (BCMA×CD3)
CRS-associated AKI in myeloma — emerging signal.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.